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Introduction {#acn351058-sec-0005}
============

Sialidosis has been gradually recognized since it was named in the 1970s.[^1^](#acn351058-bib-0001){ref-type="ref"}, [^2^](#acn351058-bib-0002){ref-type="ref"}, [^3^](#acn351058-bib-0003){ref-type="ref"} At present, we have clearly realized that the disease is an important autosomal recessive inherited lysosomal storage disorder (LSD), characterized by a deficiency in α‐*N*‐acetyl neuraminidase that results from a mutation in the neuraminidase gene (*NEU1*).[^4^](#acn351058-bib-0004){ref-type="ref"}, [^5^](#acn351058-bib-0005){ref-type="ref"} The impaired neuraminidase activity prevents oligosaccharides and glycoproteins from getting rid of the terminal sialic acid molecules, leading sialic acid‐rich macromolecules to aggregate in neurons and multiple organs.[^4^](#acn351058-bib-0004){ref-type="ref"}, [^6^](#acn351058-bib-0006){ref-type="ref"}, [^7^](#acn351058-bib-0007){ref-type="ref"} For 40 years, sialidosis has always been classified into two types on the basis of phenotype and onset age.[^8^](#acn351058-bib-0008){ref-type="ref"} Compared with type II sialidosis (ST‐2), type I (ST‐1) has a milder clinical course, usually affects adolescents or adults and is the focus of our study.

Currently, there is only one obsolete epidemiological study specializing in the Australian population for reference, with the prevalence of sialidosis estimated at 1 in 4.2 million live births.[^9^](#acn351058-bib-0009){ref-type="ref"} Furthermore, ST‐1 is rarer than ST‐2, with only hundreds of patients reported in the world according to the literature. The clinical spectrum of sialidosis is expanding and overlaps with that of many other LSDs, and establishing a diagnosis purely based on clinical manifestations is impossible.[^10^](#acn351058-bib-0010){ref-type="ref"}, [^11^](#acn351058-bib-0011){ref-type="ref"} In addition, the increased excretion pattern of urinary oligosaccharides and bound sialic acid in sialidosis is also not specific or sensitive and may be best as a screening tool.[^10^](#acn351058-bib-0010){ref-type="ref"}, [^12^](#acn351058-bib-0012){ref-type="ref"}, [^13^](#acn351058-bib-0013){ref-type="ref"}, [^14^](#acn351058-bib-0014){ref-type="ref"} Usually, researchers diagnose sialidosis by detecting the activity of neuraminidase in cultured fibroblasts or leucocytes[^13^](#acn351058-bib-0013){ref-type="ref"}, [^15^](#acn351058-bib-0015){ref-type="ref"}, [^16^](#acn351058-bib-0016){ref-type="ref"}, [^17^](#acn351058-bib-0017){ref-type="ref"}; however, this method is not accurate when simply considering this single enzyme because there is a secondary combined deficiency of neuraminidase in galactosialidosis,[^5^](#acn351058-bib-0005){ref-type="ref"} leading to many misdiagnoses in previous literature.[^18^](#acn351058-bib-0018){ref-type="ref"}, [^19^](#acn351058-bib-0019){ref-type="ref"}, [^20^](#acn351058-bib-0020){ref-type="ref"}, [^21^](#acn351058-bib-0021){ref-type="ref"} The instability of enzymes in vitro is another drawback.[^22^](#acn351058-bib-0022){ref-type="ref"} Theoretically, the severity of the phenotype correlated with the residual activity of neuraminidase, but uncertainty remains, the enzyme activity of some ST‐1 patients with late onset and chronic course is too low to be detected,[^10^](#acn351058-bib-0010){ref-type="ref"} or severe infantile ST‐2 patients have a relatively higher level of reserve enzyme activity.[^23^](#acn351058-bib-0023){ref-type="ref"} Hence, we should proceed from the root cause and make accurate diagnoses on the basis of the *NEU1* gene.

By using gene sequencing technology, researchers are expected to aggregate information on mutation types in this sporadic and rare disease, build molecular models, and establish databases that can predict phenotypes through genotypes.[^22^](#acn351058-bib-0022){ref-type="ref"}, [^24^](#acn351058-bib-0024){ref-type="ref"}, [^25^](#acn351058-bib-0025){ref-type="ref"} To date, approximately 50 mutations in the *NEU1* gene have been reported in patients with sialidosis, and the number is still increasing.[^6^](#acn351058-bib-0006){ref-type="ref"} Here, we introduce in detail five Chinese mainland ST‐1 patients from two different tertiary epilepsy centers, and we summarize all the genetically confirmed cases worldwide. Then, we determine the differences between Chinese and foreign patients. We wish to enhance the awareness of clinicians and to promote the diagnosis and treatment of the disease. To the best of our knowledge, our case series is the largest case group in mainland China to date.

Patients and Methods {#acn351058-sec-0006}
====================

Clinical analysis of five illustrative cases {#acn351058-sec-0007}
--------------------------------------------

We identified five genetically confirmed ST‐1 patients. Blood‐based gene sequencing was performed by a third‐party company with the technology of whole‐exon sequencing (WES) on HiSeq X10. The average depth of the WES ranged from 104.43X to 124.02X. The 20X coverage of WES ranged from 94.88% to 99.60%. The transcript number of the *NEU1* gene was NM_000434.3.

Patients 1--3 came from Beijing Tiantan Hospital, and the other two patients came from Peking Union Medical College Hospital. All patients gave written informed consent for participation and written consent to permit the publication of clinical details.

Patient 1 underwent 18‐fluoro‐deoxyglucose (^18^F‐FDG) positron emission tomography (PET) scans during clinical evaluations. The PET procedure and data analysis were performed according to a previous study.[^26^](#acn351058-bib-0026){ref-type="ref"} Details are described in the [Supplementary Material](#acn351058-sup-0003){ref-type="supplementary-material"}.

Comparisons to previous reports of ST‐1 patients from different regions or with different genotypes {#acn351058-sec-0008}
---------------------------------------------------------------------------------------------------

We conducted searches on the literature retrieval platforms WanFang Data (<http://www.wanfangdata.com.cn/>), CNKI (<https://www.cnki.net/>), and PubMed (<http://www.ncbi.nlm.nih.gov/pubmed/>) for articles up to October 2019 by using the title/abstract keyword "sialidosis." We selected original studies or case (series) reports that included genetically confirmed ST‐1 patients from 1996. Reference screening was conducted by two experienced neurological doctors, Tao‐Ran Li and Rui‐Juan Lv.

Articles on ST‐1 patients without genetic tests, on ST‐2 patients, and not written in English or Chinese were excluded. Researchers in Taiwan have made great contributions to sialidosis research, but several of their studies could not be included in our analysis. As the Taiwanese authors said, there were overlaps among the ST‐1 patients enrolled in these literatures,[^27^](#acn351058-bib-0027){ref-type="ref"}, [^28^](#acn351058-bib-0028){ref-type="ref"}, [^29^](#acn351058-bib-0029){ref-type="ref"} and we cannot know which patients were repeatedly included. We speculated that the 11 patients in the recent literature[^30^](#acn351058-bib-0030){ref-type="ref"} overlapped with those of previous reports[^28^](#acn351058-bib-0028){ref-type="ref"}, [^29^](#acn351058-bib-0029){ref-type="ref"}; therefore, only three genetically proven Taiwanese patients were included in our analysis.

We summarized the selected cases and compared the clinical and genetic characteristics among patients from the Chinese mainland, Taiwan, other Asian regions, and European and American regions. In addition, we also compared patients with different genotypes.

Statistics analysis {#acn351058-sec-0009}
-------------------

We subgrouped cases from the literature review based on their ethnicities and genotypes. A one‐way ANOVA was performed for group comparison of onset age, and the Games--Howell test was used for the post hoc analysis because of heteroscedasticity. For categorical variables, Fisher\'s exact test or the chi‐squared test was used for group comparison. A *P* \< 0.05 was considered significant. We performed all analyses using SPSS 13.0 software (SPSS, Chicago, IL).

Results {#acn351058-sec-0010}
=======

Clinical descriptions {#acn351058-sec-0011}
---------------------

The cases of the five Chinese mainland patients are described as follows. We provided a detailed description of patient 1 and a simple description of the rest in the [Supplementary Material](#acn351058-sup-0003){ref-type="supplementary-material"} because of their similar examination results and because of spatial limitations. There is also a detailed and comparative description in Table [1](#acn351058-tbl-0001){ref-type="table"}. All patients were right‐handed and were born at term to nonconsanguineous Chinese mainland Han parents, with no abnormal antenatal or postnatal issues of note, and all reached developmental milestones appropriately. All patients had mutations in the *NEU1* gene. Their past medical histories and family histories of seizures, ataxia, or other neurological disorders, were all unremarkable.

###### 

Clinical characteristics of Chinese mainland type I sialidosis patients in our study.

                       Patient 1, this study                                                            Patient 2, this study                                                                                                       Patient 3, this study                                                  Patient 4, this study                     Patient 5, this study
  -------------------- -------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- ----------------------------------------- ------------------------------------------------------------------------
  Age/gender           17/M                                                                             14/F                                                                                                                        31/M                                                                   20/F                                      19/M
  Past history         Easily tired after exercise; bad sports performance                              Bad sports performance                                                                                                      Unremarkable                                                           Bad sports performance                    Unremarkable
  Family history       Unremarkable                                                                     Unremarkable                                                                                                                Unremarkable                                                           Unremarkable                              Unremarkable
  Symptom onset age    12 years old                                                                     12 years old                                                                                                                17 years old                                                           10 years old                              10 years old
  Initial symptoms     GTCS                                                                             Symmetric distal neuropathic pain                                                                                           Myoclonus                                                              A and falls                               GTCS
  Seizures             GTCS; MCS                                                                        GTCS; MCS                                                                                                                   GTCS; MCS                                                              GTCS; MCS                                 GTCS; MCS
  Other symptoms       D; falls; A; hyperreflexia                                                       CI; D; falls; A; bedridden; hyperreflexia                                                                                   D; falls; A; hypertonia; hyperreflexia                                 D; bedridden                              D; A; nystagmus; unequal pupils; hyperreflexia; ankle clonus
  Visual acuity        Gradually declined                                                               Gradually declined                                                                                                          Gradually declined                                                     Gradually declined                        Gradually declined
  Aural acuity         Gradually declined; bilateral nervous deafness                                   Normal                                                                                                                      Normal                                                                 Normal                                    Normal
  Brain MRI            Normal                                                                           Widening of bilateral cerebellar sulcus                                                                                     Normal                                                                 Normal                                    Mild atrophy of cerebellar vermis and enlargement of midbrain aqueduct
  EMG                  Bilateral F‐waves were not elicited                                              Normal                                                                                                                      Normal                                                                 U                                         Neurogenic damage of extremities
  BAEP                 Normal                                                                           Normal                                                                                                                      Normal                                                                 U                                         Abnormal waveform differentiation
  VEP (P100)           Abnormal peak latency and amplitude                                              Abnormal peak latency and amplitude                                                                                         Normal                                                                 U                                         Prolonged peak latency
  SEP of upper limb    Huge potential                                                                   Huge potential                                                                                                              Huge potential                                                         U                                         Huge potential
  SEP of lower limb    Abnormal deep sensory conduction                                                 Abnormal deep sensory conduction                                                                                            Abnormal deep sensory conduction                                       U                                         Abnormal deep sensory conduction
  Ocular fundus        CRS                                                                              Punctate opacity of binocular lens; CRS                                                                                     CRS                                                                    Punctate opacity of binocular lens; CRS   CRS
  Visual field         Diffuse defect of OU visual field                                                OS, defect except the lower quadrant of nasal field; OD, enlargement of physiological blind spot                            Normal                                                                 Normal                                    Normal
  OCT                  Diffuse weakness of bilateral RNFL and GCC; hyperreflex of macular inner layer   Basically normal                                                                                                            Hyperreflex of macular inner layer                                     U                                         Hyperreflex of macular inner layer
  Blood examination    Normal                                                                           Normal                                                                                                                      Normal                                                                 Normal                                    Normal
  CSF examination      Normal                                                                           Weakly positive of oligoclonal band                                                                                         Normal                                                                 Normal                                    Normal
  Mutation of *NEU1*   c.803A \> G; c.239C \> T                                                         c.544A \> G; c.239C \> T                                                                                                    c.544A \> G; c.239C \> T                                               c.838G \> A; c.403C \> T                  c.1118T \> C; c.544A \> G
  Transmission         Hereditary mutation                                                              Hereditary mutation                                                                                                         Hereditary mutation                                                    Hereditary mutation                       U
  Therapy              LEV, 750 mg/bid; VPA, 500 mg/bid; CZP, 0.5 mg/bid                                LEV, 500 mg/bid to 750 mg/bid; CZP, 1 mg/tid                                                                                LEV, 500 mg/bid; CZP, 1 mg/qn                                          LEV, 500 mg/bid                           U
  Outcome              2 m later: GTCS, zero; MCS and A, obviously improved                             6 m later: loss of self‐sufficiency; 2 y later: GTCS, 1--3/m; MCS, daily; A and visual function deteriorated even further   2 y later: seizures, A and visual function deteriorated even further   Seizures and A improved                   U

F, female; M, male; U, unsure; GTCS, generalized tonic--clonic seizure; A, ataxia; MCS, myoclonus seizures; CI, cognitive impairment; D, dysarthria; MRI, magnetic resonance imaging; EMG, electromyography; BAEP, brainstem auditory evoked potential; VEP, visual evoked potential; SEP, somatosensory evoked potential; CRS, cherry red spot; OD, oculus dexter; OS, oculus sinister; OU, oculus unati; OCT, optical coherence tomography; RNFL, retina nerve fiber layer; GCC, ganglion cell complex; CSF, cerebrospinal fluid; LEV, levetiracetam; CZP, carbamazepine; VPA, valproic acid.
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Patient 1. A 17‐year‐old man was easily fatigued after activities and had poor sports performance since childhood. He presented with typical nocturnal generalized tonic--clonic seizures (GTCSs) 5 years ago, 1--3 times per year, which were well controlled with levetiracetam (750 mg/bid) over the past 3 years. Four years ago, he developed walking instability and frequent falls, accompanied by ambiguous language. Three years ago, his limbs trembled involuntarily, several times per day. These syndromes have deteriorated gradually. On neurological examination, he had dysarthria, ataxia of the trunk and four limbs, an enhanced bilateral tendon reflex, and negative Babinski sign. Routine examinations of blood and cerebrospinal fluid, including onconeural and neuronal surface antibodies, were normal. Abdominal ultrasonography, heart rate variability, electromyography, and nerve conduction velocity all showed no significant abnormalities except F‐waves, which were not elicited bilaterally. The pure tone threshold examination indicated bilateral neuro‐deafness. The brainstem auditory evoked potential was normal, while the visual evoked potential (VEP) showed abnormal peak latency and amplitude of P100. The somatosensory evoked potential (SEP) showed a huge potential of bilateral N20‐P25 in the upper limb pathway (Fig. [1E](#acn351058-fig-0001){ref-type="fig"}) and abnormal deep sensory conduction peripherally in the lower limb pathway. The electroencephalogram (EEG) indicated frequent polyspike and polyspike‐slow waves in bilateral central, parietal, and midline regions, accompanying myoclonic seizures (Fig. [1B](#acn351058-fig-0001){ref-type="fig"}). Ophthalmological examination found that the best‐corrected visual acuity of the left eye was 50/100 and of the right was 60/100; a dark‐red, round, spotted lesion was detected in both macular regions, suggesting cherry‐red spots (Fig. [1C](#acn351058-fig-0001){ref-type="fig"}); the bilateral eye visual fields showed diffuse defects; the optical coherence tomography (OCT) indicated bilateral diffuse weakness of the retinal nerve fiber layer and ganglion cell complex, as well as the hyperreflexivity of the macular inner layer (Fig. [1D](#acn351058-fig-0001){ref-type="fig"}). Although the brain magnetic resonance imaging (MRI) was normal (Fig. [1A](#acn351058-fig-0001){ref-type="fig"}), the ^18^F‐FDG‐PET analysis revealed hypometabolism in the left cuneus and lingual gyrus, right inferior semilunar lobule of cerebellum, left cerebellar tonsil, and culmen of the cerebellum compared to controls (Fig. [2](#acn351058-fig-0002){ref-type="fig"}).

![Examination results of patient 1. (A) Axial T1 brain magnetic resonance imaging was normal; (B) electroencephalogram showed bilateral polyspike and polyspike‐slow waves in the central, parietal, and midline regions; (C) fundus examination showed bilateral cherry‐red spots; (D) optical coherence tomography indicated bilateral diffuse weakness of the retinal nerve fiber layer and ganglion cell complex, as well as the hyperreflexivity of the macular inner layer; (E) somatosensory evoked potential showed a huge potential of bilateral N20‐P25 in the upper limb pathway.](ACN3-7-911-g001){#acn351058-fig-0001}

![Regions displaying hypometabolism in patient 1 compared with controls. ^18^F‐FDG‐PET analysis revealed hypometabolism of the left cuneus and lingual gyrus, right inferior semilunar lobule of the cerebellum, left cerebellar tonsil, and culmen of the cerebellum.](ACN3-7-911-g002){#acn351058-fig-0002}

The blood of the patient and his parents was examined by WES. Eventually, the patient was confirmed to have the heterozygous c.803A \> G (p.Y268C) and c.239C \> T (p.P80L) mutation in the *NEU1* gene, inherited from his father and mother, respectively.

Clinical characteristics of ST‐1 patients {#acn351058-sec-0012}
-----------------------------------------

Eventually, we identified 35 articles according to the literature review (detailed information in the [Supplementary Material](#acn351058-sup-0003){ref-type="supplementary-material"}). In addition to our 5 patients, another 72 ST‐1 patients from these articles were included for comparison. We collected clinical information as much as possible according to the description of the original literature, and we tried our best to ensure accuracy. The specific clinical characteristics of the 77 ST‐1 patients are summarized in Table [1](#acn351058-tbl-0001){ref-type="table"} and the Supplementary Tables (Table [S1](#acn351058-sup-0001){ref-type="supplementary-material"} is a continuation of Table [1](#acn351058-tbl-0001){ref-type="table"} and describes the other 7 mainland patients reported in the literature; Table [S2](#acn351058-sup-0002){ref-type="supplementary-material"} describes 65 patients from other regions). In Table [2](#acn351058-tbl-0002){ref-type="table"}, we summarized the data from all patients and compared the clinical data according to the origin of the patients.

###### 

Comparison of genetically confirmed ST‐1 patients from different ethnic groups.

  Clinical characteristics       Chinese mainland      Taiwan                    Other Asian regions                                European and American regions              Total
  ------------------------------ --------------------- ------------------------- -------------------------------------------------- ------------------------------------------ ---------------------
  No. of cases                   12                    23                        10                                                 32                                         77
  Ethnicity                      The Han nationality   Taiwanese                 East‐Asian, 1; Indian, 3; Korean, 1; Japanese, 5   European, 27; American, 4; Ecuadorian, 1   \\
  Onset age (y)                  10.8 ± 2.7 (10 Ava)   18.0 ± 6.6 (23 Ava)\*\*   15.8 ± 6.3 (9 Ava)\*                               16.9 ± 6.7 (24 Ava)\*\*                    16.0 ± 6.7 (66 Ava)
  M/F                            7/5                   17/6                      6/4                                                9/18 (27 Ava)                              39/33 (72 Ava)
  MCS                            100% (12, 12 Ava)     100% (23, 23 Ava)^\#^     90.0% (9, 10 Ava)^\#^                              93.3% (28, 30 Ava)^\#^                     96.0% (72, 75 Ava)
  Ataxia                         100% (9, 9 Ava)       95.7% (22, 23 Ava)^\#^    100% (10, 10 Ava)^\#^                              89.3% (25, 28 Ava)^\#^                     94.3% (66, 70 Ava)
  Blurred vision                 100% (11, 11 Ava)     81.8% (18, 22 Ava)^\#^    28.6% (2, 7 Ava)\*\*                               55.6% (10, 18 Ava)\*                       67.2% (39, 58 Ava)
  CRS                            72.7% (8, 11 Ava)     27.3% (6, 22 Ava)\*       90.0% (9, 10 Ava)^\#^                              55.2% (16, 29 Ava)^\#^                     54.2% (39, 72 Ava)
  VEP (abnormal P100)            83.3% (5, 6 Ava)      95.5% (21, 22 Ava)^\#^    100% (2, 2 Ava)^\#^                                33.3% (3, 9 Ava)^\#^                       79.5% (31, 39 Ava)
  SEP (GCP)                      100% (4, 4 Ava)       100% (22, 22 Ava)^\#^     100% (2, 2 Ava)^\#^                                100% (7, 7 Ava)^\#^                        100% (35, 35 Ava)
  Brain MRI                      25.0% (2, 8 Ava)      42.1% (8, 19 Ava)^\#^     42.9% (3, 7 Ava)^\#^                               37.5% (6, 16 Ava)^\#^                      38.8% (19, 49 Ava)
  *NEU1* mutation, c.544A \> G   75.0% (9, 12 Ava)     100% (23, 23 Ava)\*       10.0% (1, 10 Ava)\*\*                              0% (0, 32 Ava)\*\*                         42.9% (33, 77 Ava)
  *NEU1* mutation, c.239C \> T   50.0% (6, 12 Ava)     13.0% (3, 23 Ava)\*       10.0% (1, 10 Ava)^\#^                              0% (0, 32 Ava)\*\*                         13.0% (10, 77 Ava)

ST‐1, Type I sialidosis; Ava, available; M, male; F, female; MCS, myoclonus seizures; CRS, cherry red spot; VEP, visual evoked potential; SEP, somatosensory evoked potential; GCP, giant cortical potential; MRI, magnetic resonance imaging. European: German, 3; Dutchman, 3; Greek, 1; French, 3; Turkey, 3; Czech, 1; Italian, 9; Spaniard, 1; Portuguese, 3. Compared with Chinese mainland patients, \**P* \< 0.05, \*\**P* \< 0.01, ^\#^ *P* \> 0.05.
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Of the 77 patients, 12 were from mainland China, 23 were from Taiwan, 10 were from other Asian regions outside China, mainly Japan (5) and India (3), and 32 were from European and American regions, mainly from Europe (27). According to the information presently available, the proportion of males was approximately 54.2% (72 available); the mean age of onset was 16.0 ± 6.7 years (66 available). The most common symptoms were myoclonic seizures (96.0%, 75 available), followed by ataxia (94.3%, 70 available), and blurred vision (67.2%, 58 available). Other manifestations were difficult to count due to limited information, such as GTCSs, dysarthria, dysphagia, hearing loss, or cognitive impairment. Notably, though with a limited number of patients, the available data showed that the proportion of giant cortical potentials in SEP reached an amazing 100% (35 available), and 79.5% (39 available) of patients presented abnormal VEP, while cherry‐red spots were reported in only 39 of 72 (54.2%) patients. Abnormalities on brain MRI were found in 19 of 49 (38.8%) patients, 16/19 (84.2%) showed brain atrophy, and the remaining three showed a widening of the bilateral cerebellar sulcus (patient 2), frontotemporal encephalomalacia, and cerebellar meningocele.[^29^](#acn351058-bib-0029){ref-type="ref"} Because of autosomal recessive inheritance, each patient has two mutation sites (perhaps homozygosity) in the *NEU1* gene, corresponding to two mutation "occurrences." Consequently, we acquired 150 mutation "occurrences" in these 77 patients (we could obtain only one mutation site for patients 60, 64, 66, and 67[^12^](#acn351058-bib-0012){ref-type="ref"}, [^24^](#acn351058-bib-0024){ref-type="ref"}, [^25^](#acn351058-bib-0025){ref-type="ref"}). As shown in Figure [3](#acn351058-fig-0003){ref-type="fig"}, there were 8 mutation types in Chinese mainland patients, 6 types in Taiwanese patients, 14 types in other Asian patients, and 30 types in European and American patients. In total, 48 different mutation types were identified. The most frequent mutation type was c.544A \> G, which occurred 51 times in 33 persons, followed by c.239C \> T (10 times, 10 persons), c.679G \> A (7 times, 7 persons), c.200G \> T (6 times, 3 persons), and c.982G \> A (4 times, 4 persons); other types occurred only 1--3 times.

![Mutation types of ST‐1 patients. (A--D) show the type and number of mutations in ST‐1 patients from the Chinese mainland, Taiwan, other Asian regions, and European and American regions, respectively. P means the number of patients; T means the mutation times. Each patient has two mutation sites (perhaps homozygosity) in the *NEU1* gene, corresponding to two mutation "occurrences." A mutation in the intron region of an Indian patient, g.2869A \> T (1P, 1T), and a c.1258G \> T (2P, 2T) mutation in the 3'‐UTR regions of two Americans patients are not marked in the figure.](ACN3-7-911-g003){#acn351058-fig-0003}

Comparison of patients from different ethnic groups {#acn351058-sec-0013}
---------------------------------------------------

As shown in Table [2](#acn351058-tbl-0002){ref-type="table"}, we divided patients into the abovementioned four groups according to their origins to assess whether regions and races have an impact on genotypes or phenotypes of ST‐1. We found that the onset age of patients from mainland China was significantly lower than that of the other three groups, and there was no significant difference among patients from other regions. There is no point in comparing the ratio of men to women for autosomal diseases. The major symptoms (myoclonus and ataxia) were similar among these four groups. Notably, compared with the astounding incidence rate of visual impairment in Chinese mainland and Taiwanese patients, 100% (11/11) and 81.8% (18/22), respectively, the incidence was obviously lower in patients from other Asian regions, only 28.6% (2/7). Cherry‐red spots were reported less frequently in Taiwanese patients than in the other three groups (27.3% vs. 55.2%--90.0%). All patients in the four groups had abnormal giant cortical potentials in SEP, while the VEP of patients from European and American regions tended to be less likely to be abnormal than that of patients from the other three groups (33.3% vs. 83.3%--100%). The probability of brain MRI abnormalities was between 25% and 42.9%, and there was no difference among groups. As shown in Figure [3](#acn351058-fig-0003){ref-type="fig"} and Table [2](#acn351058-tbl-0002){ref-type="table"}, importantly, up to 9/12 (75%) Chinese mainland patients and 23/23 (100%) Taiwanese patients carried the c.544A \> G mutation in the *NEU1* gene, which was much higher than proportion found in the other Asian group and the European and American group (10.0% and 0%, respectively). In addition, the homozygous proportion of Taiwanese patients (16/23, 69.6%) was higher than that of Chinese mainland patients (2/9, 22.2%). Another concern was that Chinese mainland patients were also more likely to carry the c.239C \> T (6/12, 50%) mutation than other groups (0%--13%).

Comparison of patients with different genotypes {#acn351058-sec-0014}
-----------------------------------------------

To further understand the genotype--phenotype correlations, we divided patients according to their mutation types. As shown in Table [3](#acn351058-tbl-0003){ref-type="table"}, eight patients had the heterozygous c.544A \> G and c.239C \> T mutation and 18 had the homozygous c.544A \> G mutation; all of them were from mainland China or Taiwan. The next high‐frequency genotypes were heterozygous c.649G \> A and c.727G \> A, homozygous c.200G \> T and heterozygous c.679G \> A, and c.913C \> T. All three genotypes appeared three times; furthermore, the latter two belonged to familial aggregations, both coming from siblings of the same family. Four mutation types appeared two times, which are also shown in Table [3](#acn351058-tbl-0003){ref-type="table"}. The remaining 34 genotypes appeared only once, and the clinical details can be found in Table [1](#acn351058-tbl-0001){ref-type="table"} and the Supplementary Tables.

###### 

Comparison of genetically confirmed ST‐1 patients with different genotypes.

  Mutation types                  c.544A \> G; c.239C \> T   Homozygous c.544A \> G    c.649G \> A; c.727G \> A   Homozygous c.200G \> T   c.679G \> A; c.913C \> T   c.1195_1200dup; c.679G \> A   c.159G \> A; c.1127G \> T   c.914G \> A; c.625delG   c.700G \> A; c.1021C \> T
  ------------------------------- -------------------------- ------------------------- -------------------------- ------------------------ -------------------------- ----------------------------- --------------------------- ------------------------ ---------------------------
  Ethnic regions (No.)            8                          18                        3                          3                        3                          2                             2                           2                        2
  mainland China                  5                          2                         0                          0                        0                          0                             0                           0                        0
  Taiwan                          3                          16                        0                          0                        0                          0                             0                           0                        0
  other Asian regions             0                          0                         3^a^                       0                        0                          0                             0                           0                        0
  European and American regions   0                          0                         0                          3^b^                     3^b^                       2^b^                          2^b^                        2^a^                     2^a^
  Onset age (y)                   11.6 ± 3.1 (8 Ava)         20.6 ± 6.3 (16 Ava)\*\*   21.3 ± 9.3 (3 Ava)         23.3 ± 1.5 (3 Ava)       27.3 ± 4.0 (3 Ava)         10.5 ± 2.1 (2 Ava)            16.0 ± 1.4 (2 Ava)          17.0 ± 0 (2 Ava)         26^c^
  M/F                             4/4                        14/4                      2/1                        1/2                      1/2                        0/2                           0/2                         0/2                      1/0^c^
  MCS                             100% (8, 8 Ava)            100% (18, 18 Ava)^\#^     100% (3, 3 Ava)            100% (3, 3 Ava)          100% (3, 3 Ava)            100% (2, 2 Ava)               100% (2, 2 Ava)             100% (2, 2 Ava)          100% (2, 2 Ava)
  Ataxia                          100% (6, 6 Ava)            94.1% (16, 17 Ava)^\#^    100% (3, 3 Ava)            100% (3, 3 Ava)          100% (3, 3 Ava)            50.0% (1, 2 Ava)              100% (2, 2 Ava)             100% (2, 2 Ava)          100% (1, 1 Ava)
  Blurred vision                  100% (8, 8 Ava)            81.3% (13, 16 Ava)^\#^    50.0% (1, 2 Ava)           0% (0, 3 Ava)            0% (0, 2 Ava)              100% (2, 2 Ava)               U                           0% (0, 2 Ava)            100% (2, 2 Ava)
  CRS                             75.0% (6, 8 Ava)           6.3% (1, 16 Ava)\*\*      100% (3, 3 Ava)            0% (0, 3 Ava)            0% (0, 2 Ava)              100% (2, 2 Ava)               50.0% (1, 2 Ava)            0% (0, 2 Ava)            100% (2, 2 Ava)
  VEP (abnormal P100)             80.0% (4, 5 Ava)           93.8% (15, 16 Ava)^\#^    U                          0% (0, 3 Ava)            0% (0, 3 Ava)              U                             U                           U                        U
  SEP (GCP)                       100% (5, 5 Ava)            100% (15, 15 Ava)^\#^     U                          100% (3, 3 Ava)          100% (3, 3 Ava)            U                             U                           100% (1, 1 Ava)          U
  Brain MRI                       33.3% (1, 3 Ava)           43.8% (7, 16 Ava)^\#^     0% (0, 2 Ava)              33.3% (1, 3 Ava)         0% (0, 3 Ava)              0% (0, 2 Ava)                 U                           100% (1, 1 Ava)          100% (1, 1 Ava)

ST‐1, Type I sialidosis; Ava, available; M, male; F, female; MCS, myoclonus seizures; CRS, cherry red spot; VEP, visual evoked potential; SEP, somatosensory evoked potential; GCP, giant cortical potential; MRI, magnetic resonance imaging; U, unsure. a, the patients came from different families; b, the patients were siblings. c, only one patient's data can be acquired. Compared with the heterozygous c.544A \> G and c.239C \> T mutation patients, \*\**P* \< 0.01, ^\#^ *P* \> 0.05.
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Considering the limited sample size, the unavailability of some data and familial aggregations, we made statistical comparisons only of the two most frequent mutation types: the heterozygous c.544A \> G and c.239C \> T mutation and the homozygous c.544A \> G mutation. We found differences in the onset age and incidence of cherry‐red spots; the onset age of the former genotype was 11.6 ± 3.1 years old, which was significantly lower than that of the latter (20.6 ± 6.3 years), while only one of the 16 homozygous c.544A \> G mutation patients had cherry‐red spots, which was significantly lower than that of the patients with heterozygous c.544A \> G and c.239C \> T mutation (75.0%). We found no other differences, such as seizures or ataxia (Table [3](#acn351058-tbl-0003){ref-type="table"}).

Discussion {#acn351058-sec-0015}
==========

In this study, we included five ST‐1 patients from two tertiary epilepsy centers in mainland China. They have similar manifestations, examination results and mutation types (3/5 have the c.544A \> G or c.239C \> T mutation). Then, we explored previous literature, hoping to further determine the influence of regions and ethnicities on ST‐1. Finally, we included 12 patients from mainland China,[^24^](#acn351058-bib-0024){ref-type="ref"}, [^31^](#acn351058-bib-0031){ref-type="ref"}, [^32^](#acn351058-bib-0032){ref-type="ref"}, [^33^](#acn351058-bib-0033){ref-type="ref"}, [^34^](#acn351058-bib-0034){ref-type="ref"} 23 from Taiwan, 10 from other Asian regions, and 32 from Europe and America. We summarized their clinical characteristics and made a horizontal comparison. To the best of our knowledge, this study provides the largest number of patients from mainland China to date and includes all known genetically confirmed ST‐1 patients for the first time.

According to the present 77 ST‐1 patients, we found that there was no sex difference, and the clinical manifestations usually started in adolescence (16.0 ± 6.7 years). A similar conclusion was obtained in another study where the onset age was 15.5 ± 5.5 years.[^35^](#acn351058-bib-0035){ref-type="ref"} Although there may be overlaps of the enrolled patients, three different studies suggested that the average age of onset in Taiwanese patients was 19.8 ± 6.2,[^28^](#acn351058-bib-0028){ref-type="ref"} 19.4 ± 6.1,[^29^](#acn351058-bib-0029){ref-type="ref"} and 18.3 ± 9.5 years,[^30^](#acn351058-bib-0030){ref-type="ref"} respectively, which was also similar to our result (18.0 ± 6.6 years). Moreover, we found that the mean onset age in the Caucasian population did not change after enlarging the sample size and enrolling African Americans in our study (16.9 ± 6.7 years) when compared with a previous study (16.7 ± 6.3 years).[^35^](#acn351058-bib-0035){ref-type="ref"} Obviously, ST‐1 patients in mainland China were younger than all the other regions, only 10.8 ± 2.7 years, but the reasons for this observation are elusive. Although the onset age of the patients with heterozygous c.544A \> G and c.239C \> T mutation was lower than that of the patients with homozygous c.544A \> G mutation, we considered that the result was also influenced by regional factors. Except for one patient whose onset age was 17 years, the onset age of the other nine patients from mainland China was 7--12 years, independent of genotypes. Further studies are needed to clarify this.

Consistent with previous studies,[^28^](#acn351058-bib-0028){ref-type="ref"}, [^29^](#acn351058-bib-0029){ref-type="ref"}, [^30^](#acn351058-bib-0030){ref-type="ref"}, [^35^](#acn351058-bib-0035){ref-type="ref"} almost all patients had myoclonus and ataxia. The incidence of epilepsy was between 72.5% and 83.3%,[^28^](#acn351058-bib-0028){ref-type="ref"}, [^29^](#acn351058-bib-0029){ref-type="ref"}, [^30^](#acn351058-bib-0030){ref-type="ref"}, [^35^](#acn351058-bib-0035){ref-type="ref"} mainly myoclonus seizures and GTCSs, while focal tonic seizures[^35^](#acn351058-bib-0035){ref-type="ref"} or partial complex seizures[^25^](#acn351058-bib-0025){ref-type="ref"} or only EEG discharge[^13^](#acn351058-bib-0013){ref-type="ref"} can also exist. Notably, visual impairment in patients from other Asian regions (28.6%) was significantly lower than those observed in the Chinese mainland group and the Taiwanese group (100% and 81.8%, respectively); VEP abnormality in patients from European and American regions (33.3%) seem to be rare, significantly lower than those observed in the Chinese mainland group and the Taiwanese group (83.3% and 95.5%, respectively). In addition, visual impairment in patients from other Asian regions and VEP abnormality in patients from European and American regions were also significantly lower than previous studies of Taiwanese (75%--100% and 81.8%--94.1%, respectively).[^28^](#acn351058-bib-0028){ref-type="ref"}, [^29^](#acn351058-bib-0029){ref-type="ref"}, [^30^](#acn351058-bib-0030){ref-type="ref"} Curiously, the proportion of visual impairment and VEP abnormality did not match that found in the other Asian population, and we speculated that this was related to the integrity of the patients\' examinations, because many patients had completed only one of them, causing information deviations and statistical errors. Ahn et al*.* found that early‐onset patients are more likely to have visual impairment than late‐onset patients.[^36^](#acn351058-bib-0036){ref-type="ref"} However, the Taiwanese patients in our study challenged that result; they had the highest average onset age and were also likely to have impairment. It was once thought that cherry‐red spots were inevitable in the course of ST‐1,[^37^](#acn351058-bib-0037){ref-type="ref"} but now, we have realized that their observation is not sensitive or specific and just plays a suggestive role; these spots can disappear as the disease progresses[^17^](#acn351058-bib-0017){ref-type="ref"} or emerge 20 years after the disease onset.[^16^](#acn351058-bib-0016){ref-type="ref"} However, the presence of cherry‐red spots in progressive myoclonic epilepsy patients strongly suggests a diagnosis of sialidosis.[^6^](#acn351058-bib-0006){ref-type="ref"} Contrary to the incidence in other regions (55.2%--72.7%) in our study or in a previous report of a Caucasian population (61.1%),[^35^](#acn351058-bib-0035){ref-type="ref"} only 6 out of 22 Taiwanese patients have cherry‐red spots detected. The difference may be partially determined by the homozygous c.544A \> G mutation, which is known to have higher residual enzymatic activity with similar half‐life and cause no obvious structural change in the lysosomal multienzyme complex. On the basis of the results, we supposed that late‐onset patients tend to be free of spots, probably due to the inclusion of Taiwanese patients.[^36^](#acn351058-bib-0036){ref-type="ref"} Brain MRI is not necessary for the diagnosis because it is mostly normal or parts show nonspecific atrophy (32.7% in our study). However, similar to previous reports,[^38^](#acn351058-bib-0038){ref-type="ref"}, [^39^](#acn351058-bib-0039){ref-type="ref"} patient 1, with normal MRI, showed bilateral hypometabolism in the cerebellum and occipital lobe, indicating that ^18^F‐FDG‐PET is more sensitive for the detection of abnormalities than MRI. Furthermore, a complete ophthalmic examination, including the fundus, visual field, and OCT, is necessary for the comprehensive assessment of ST‐1,[^16^](#acn351058-bib-0016){ref-type="ref"}, [^34^](#acn351058-bib-0034){ref-type="ref"}, [^40^](#acn351058-bib-0040){ref-type="ref"} and other examinations, such as EEG and SEP, are likely to be 100% abnormal.[^28^](#acn351058-bib-0028){ref-type="ref"}, [^29^](#acn351058-bib-0029){ref-type="ref"}, [^30^](#acn351058-bib-0030){ref-type="ref"}, [^35^](#acn351058-bib-0035){ref-type="ref"} Currently, there is no consensus on the diagnosis of ST‐1, but the following typical manifestations can be used to suspect the diagnosis. For those patients whose clinical presentation is consistent with adolescent onset of progressive myoclonic epilepsy, their detailed ophthalmic examination reveals cherry‐red spots, and clinicians should implement genetic tests to determine a definite diagnosis of ST‐1 as early as possible.

The five patients in our study showed some relatively rare signs, such as neuropathic pain (patient 2), cognitive impairment (patient 2), and deafness (patient 1), all of which have been reported previously.[^17^](#acn351058-bib-0017){ref-type="ref"}, [^23^](#acn351058-bib-0023){ref-type="ref"}, [^41^](#acn351058-bib-0041){ref-type="ref"} Other atypical symptoms should also be noted, including scoliosis,[^10^](#acn351058-bib-0010){ref-type="ref"}, [^31^](#acn351058-bib-0031){ref-type="ref"}, [^42^](#acn351058-bib-0042){ref-type="ref"} vertebral deformities,[^10^](#acn351058-bib-0010){ref-type="ref"} back or hip pain,[^10^](#acn351058-bib-0010){ref-type="ref"}, [^14^](#acn351058-bib-0014){ref-type="ref"} syringomyelia,[^10^](#acn351058-bib-0010){ref-type="ref"} and avascular osteonecrosis[^14^](#acn351058-bib-0014){ref-type="ref"}, [^43^](#acn351058-bib-0043){ref-type="ref"}; an ST‐1 patient can even develop serious dysphagia and suffer from recurrent bronchopneumonia[^44^](#acn351058-bib-0044){ref-type="ref"} or be misdiagnosed with conversion disorder.[^14^](#acn351058-bib-0014){ref-type="ref"} Patient 5 had unequal pupils, but we are not sure whether this is related to the disease. These atypical symptoms further implied that *NEU1* can indeed be mutated in the absence of typical clinical signs, further complicating the diagnosis of sialidosis.

Enzyme‐dependent diagnosis may be inappropriate, because its activity is likely to be affected by the sampling sites and experimental conditions, and the detection of neuraminidase alone is not specific.[^4^](#acn351058-bib-0004){ref-type="ref"}, [^5^](#acn351058-bib-0005){ref-type="ref"} It would also be impossible to make any accurate predictions as to phenotypes purely from biochemical evidence.[^22^](#acn351058-bib-0022){ref-type="ref"} Most patients presented near‐zero activity for the defective enzyme, but not all of them manifested the most severe forms of the disease.[^10^](#acn351058-bib-0010){ref-type="ref"}, [^22^](#acn351058-bib-0022){ref-type="ref"} Thus, it is conceivable that environmental factors, including diet and different types of environmental exposure, in addition to neuraminidase mutation, may influence the penetrance of the disease or phenotype.[^5^](#acn351058-bib-0005){ref-type="ref"}, [^23^](#acn351058-bib-0023){ref-type="ref"} Currently, gene detection is essential for the diagnosis of sialidosis and is of great importance in the early diagnosis, early intervention, genetic counseling, prognosis prediction, and possible gene therapy in the future. We found substantial genetic heterogeneity among different regions. The c.544A \> G and c.239C \> T mutations were not found in the European and American population and were rarely seen in the other Asian population; however, they were the most common mutation types in mainland China (75% and 50%) and Taiwanese (100% and 13%) patients, indicating their same root and homology. The homozygous c.544A \> G mutation of Taiwanese patients reached 69.6% (16/23), which may be due to small‐scale intermarriage limited to the island. The two common mutation types of Europeans and Americans were homozygous c.200G \> T (3/32, 9.4%) and heterozygous c.679G \> A and c.913C \> T (3/32, 9.4%), both in three patients from two different families in Italy.[^10^](#acn351058-bib-0010){ref-type="ref"} The heterozygous c.649G \> A and c.727G \> A mutation (3/10, 10.0%) is probably the most common type in Japanese patients, coming from three different families.[^7^](#acn351058-bib-0007){ref-type="ref"}, [^45^](#acn351058-bib-0045){ref-type="ref"} Other mutation types were rare and sporadic. We speculated that different countries or regions retain their own unique mutation types of ST‐1.

Our study also had some limitations. First, the retrospective analysis of the literature had the following inherent limitations: the diverse vocabularies could have led to a certain degree of interpretation, and the description of clinical features and typical examinations also differed from one article to another. Second, we tried our best to include as many genetically confirmed ST‐1 patients as possible, but there may be omissions, and importantly, articles written in languages other than English or Chinese were excluded, which may also cause statistical deviation. Third, the diagnosis of patient 59,[^23^](#acn351058-bib-0023){ref-type="ref"} who developed characteristics of ST‐2 with coarse facies and dysmorphic features, was questionable, but we followed the original author\'s viewpoint. Fourth, patients 53 and 55 may be too young to show symptoms such as epilepsy or ataxia or others.[^13^](#acn351058-bib-0013){ref-type="ref"}, [^23^](#acn351058-bib-0023){ref-type="ref"} Fifth, we did not obtain all patients' FDG‐PET image analysis data. Finally, since almost all our patients had poor prognosis, it remains challenging to provide treatment advice. Considering the shortcomings of our research and the limitations in this field, multicenter collaboration to include more subjects and long‐term follow‐up are needed in the future.
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